Inclusion Criteria:
1. Confirmed diagnosis of childhood apraxia of speech/verbal apraxia by a qualified professional (SLP) based on established guidelines
2. Male and female, age 36 months - 6 years (inclusive)
3. Ability to comprehend and use Standard American English
Exclusion Criteria:
1. Children unable to tolerate oral supplementation
2. Known allergy to fish oil, palm kernel oil or other ingredients in investigational drug
3. Medical or genetic condition that in the opinion of the PI/Co-Is may affect participation and compromise results (including significant receptive language delay, moderate-severe cognitive delay, complex medical history, hearing loss, cerebral palsy, history of traumatic brain injury or severe anoxic event, Down's syndrome)
4. Known seizure disorder or history of febrile seizures
5. History of cardiac dysrhythmia or abnormal ECG at baseline
6. A prothrombin time test with an international normalised ratio (PT/INR) \>1.2
7. Use of blood thinners, including chronic aspirin, chronic NSAIDS, warfarin etc.
8. A history of PUFA or vit E supplementation use within 3 months prior to enrollment in the study
9. On an elimination diet for \< 3 months (gluten, casein, yeast free etc.) prior to enrollment, or planning to initiate a special diet during the study
10. Recent reintroduction of food items from elimination diet \< 3 months
11. On any additional nutritional interventions/supplements \< 3 months (i.e. high dose vitamins/minerals that exceed what would be found in a children's multivitamin supplement etc., probiotics)
12. Any new chronic medication \< 3 months prior to enrollment (stable doses \> 3 months allowed; medications for acute illness allowed including antipyretics, antibiotics, asthma medication)
13. Anticipated initiation of new chronic medication during study timeline including new attention-deficit/hyperactivity disorder (ADHD) medications, other behavior medications
14. Plans to try additional complementary interventions or diets during the study period
15. Planned surgery during or within 4 weeks after conclusion of trial
Inclusion Criteria for Expanded Cohort:
1. Working Diagnosis of CAS, or intestinal lymphangiectasia, or fat malabsorption syndrome (in isolation or associated with other medical conditions such as cystic fibrosis, celiac disease, etc.)
2. Male and female, aged ≥2 years
3. Ability to comprehend and use Standard American English
Exclusion Criteria for Expanded Cohort:
1. Subjects unable to tolerate oral supplementation
2. Known allergy to fish oil, palm kernel oil or other ingredients in investigational drug
3. History of cardiac dysrhythmia or abnormal ECG at baseline
4. PT-INR \>1.2. A clinical lab performed within a month of enrollment will be accepted to meet this exclusion criteria
5. Use of blood thinners, including chronic aspirin, chronic NSAIDS, warfarin etc. (Symptomatic use of NSAIDS for acute fever or pain permitted)
